Lymphoma Research Reagents — CD20, CD19, CD30, PD-1/PD-L1, CD22, CD38 Antibodies & Recombinant Proteins

CD20 / MS4A1
CD20 is the most established lymphoma target — the antigen for rituximab (first anti-cancer mAb approved, 1997), obinutuzumab, ofatumumab, and the new generation of CD20×CD3 bispecific T-cell engagers (glofitamab, epcoritamab, mosunetuzumab). abinScience provides one of the broadest CD20 reagent panels available, including biosimilar-grade reference antibodies for all major anti-CD20 therapeutics, CD20×CD3 bispecific reference antibodies, recombinant anti-CD20 antibodies, InVivoMAb, nanobodies, recombinant CD20 proteins (human, cynomolgus, mouse), polyclonal antibodies, and ELISA kits. Browse all CD20 products →

CD19
CD19 is the target for CAR-T therapies (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel), ADCs (loncastuximab tesirine), and bispecific antibodies (blinatumomab, duvortuxizumab). abinScience offers anti-CD19 reference antibodies (coltuximab, denintuzumab, obexelimab), bispecific references, recombinant antibodies, recombinant CD19 proteins (multi-species), nanobodies, and InVivoMAb. Browse all CD19 products →

CD22 / Siglec-2
CD22 is the target for ADCs (inotuzumab ozogamicin for ALL, moxetumomab pasudotox for HCL) and CD22-directed CAR-T therapies. abinScience offers reference antibodies (epratuzumab, bectumomab, pinatuzumab), recombinant anti-CD22 antibodies, multi-species CD22 proteins, and polyclonal antibodies. Browse all CD22 products →

CD79a / CD79b
CD79b is the target for the ADC polatuzumab vedotin (Polivy, approved for DLBCL). CD79a/CD79b heterodimer forms the signaling component of the BCR complex. Available: biosimilar reference antibodies (polatuzumab, iladatuzumab), recombinant anti-CD79a/b antibodies, recombinant proteins, monoclonal antibodies, and InVivoMAb. Browse all CD79 products →

CD30 / TNFRSF8
CD30 is the hallmark marker of classical Hodgkin lymphoma Reed-Sternberg cells and the target for brentuximab vedotin (Adcetris, approved for HL and ALCL). abinScience offers biosimilar reference antibodies (brentuximab, iratumumab), recombinant anti-CD30 antibodies, recombinant CD30 proteins (human, cynomolgus, mouse), and polyclonal antibodies. Browse all CD30 products →

CD38
CD38 is the target for daratumumab (Darzalex, approved for myeloma and increasingly studied in NHL/T-cell lymphomas) and isatuximab. abinScience offers reference antibodies (daratumumab, isatuximab, mezagitamab, felzartamab), recombinant anti-CD38 antibodies, nanobodies, recombinant CD38 proteins, and monoclonal antibodies. Browse all CD38 products →

PD-1 / PDCD1
PD-1 checkpoint blockade (nivolumab, pembrolizumab) is approved for relapsed/refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. abinScience provides one of the deepest PD-1 reagent portfolios in the industry — including biosimilar reference antibodies for all major anti-PD-1 therapeutics (nivolumab, pembrolizumab, cemiplimab, dostarlimab, and clinical-stage candidates), InVivoMAb for in vivo immune checkpoint studies, recombinant anti-PD-1 antibodies, nanobodies, recombinant PD-1 proteins (human, cynomolgus, mouse, rat), and monoclonal antibodies. Browse all PD-1 products →

PD-L1 / CD274 / B7-H1
PD-L1 is expressed on lymphoma cells and in the tumor microenvironment, and is the target for atezolizumab, durvalumab, and avelumab. abinScience offers reference antibodies for all approved and clinical anti-PD-L1 therapeutics, InVivoMAb (including bispecific PD-L1×CTLA-4 formats), recombinant anti-PD-L1 antibodies, nanobodies, recombinant PD-L1 proteins (multi-species), monoclonal antibodies, and polyclonal antibodies. Browse all PD-L1 products →

What are biosimilar-grade reference antibodies and how are they used?
Biosimilar-grade (Research Grade, RUO) antibodies are produced with sequences identical to approved or clinical-stage therapeutic antibodies — such as rituximab (anti-CD20), brentuximab (anti-CD30), and nivolumab (anti-PD-1). They are used as positive controls in binding/neutralization assays, reference standards for PK (pharmacokinetic) and ADA (anti-drug antibody) bioanalytical method development, and bioactivity benchmarks in biosimilar and novel therapeutic development programs.

Do you have bispecific antibody reference standards for lymphoma?
Yes. abinScience provides biosimilar-grade bispecific reference antibodies for the new generation of CD20×CD3 T-cell engagers: glofitamab (Columvi), epcoritamab (Epkinly), mosunetuzumab (Lunsumio), odronextamab, and plamotamab. We also offer CD19×CD3 bispecific references (duvortuxizumab). These are essential for PK/ADA assay development and bioactivity comparison in bispecific antibody programs.

Which target should I choose for DLBCL research?
The major therapeutic targets for DLBCL are CD20 (rituximab R-CHOP backbone, bispecifics), CD79b (polatuzumab vedotin), CD19 (CAR-T, loncastuximab tesirine), and PD-L1 (immune checkpoint). Our reagent portfolio covers all four targets with antibodies, proteins, and ELISA kits — enabling comprehensive drug mechanism studies, biomarker validation, and companion diagnostic development.

Explore reagents for related research areas:

CD20 Reagents PD-1 Reagents PD-L1 Reagents CD19 Reagents CD30 Reagents CD38 Reagents